Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cassiopea SpA    SKIN   IT0005108359

CASSIOPEA SPA

(SKIN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/19/2018 | 01:05am EDT

Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts

Lainate, Italy - 19 July 2018 - Cassiopea SpA (SIX: SKIN), a clinical-stage pharmaceutical company developing and commercializing innovative medical dermatology products, today announced that the proof of concept phase II clinical trial for its CB-06-02 topical 15% immune modulator tellurium-based gel for the treatment of external genital warts in women demonstrated statistically significant successful complete clearance rates in the PP population and successful complete clearance rates in the ITT population.

The Phase II, multicenter, randomized, double-blinded, vehicle (placebo) controlled study evaluated the efficacy, safety and tolerability of topical CB-06-02 15% gel as compared to vehicle in female subjects with external genital warts. The study was conducted in six sites in Israel. 68 women 18 years of age and older were treated in two groups. Either CB-06-02 15% or vehicle gel were administered topically once a day with the gel being left on the skin overnight. The primary efficacy endpoint evaluated in the trial was the proportion of subjects achieving complete clearance of external genital warts using CB-06-02 15% or vehicle by the end (14th week) of treatment. Several other secondary endpoints are also being evaluated.

Top Line Efficacy Results in Primary Endpoint

In the PP population (56 subjects), 75% of the CB-06-02 group achieved complete clearance of external genital warts while 40.6% of subjects achieved complete clearance using vehicle. These results are statistically significant with a p value of 0.0111. In the ITT population (67 subjects), 56.3% of the CB-06-02 group achieved complete clearance of external genitals warts while 37.1% of subjects achieved complete clearance using vehicle.

Diana Harbort, CEO Cassiopea, said: "We are very encouraged by these results, which pave the way for further successful development. These data will allow us to continue working to bring this new mechanism for the treatment of genital warts to patients and their physicians. We will now focus on doing the development work to prepare for a dose ranging trial."

Safety Results

There were no treatment-related serious adverse events among patients treated with CB-06-02.

About Genital Warts

Genital warts, also known as Condyloma Acuminata, have their clinical manifestation in ~1% of the sexually active population. The Human Papilloma Virus (HPV) types 6 and 11 are particularly associated with genital warts and are responsible for ~90% of the cases. The warts manifest themselves as external visible lesions of the anogenital area.

About CB-06-02

CB-06-02, a NCE, immune modulator is being developed for the treatment of genital warts. Cassiopea believes it is the first potential treatment for this condition based on tellurium, a rare element. It acts as a low-toxicity immunomodulator in supporting the natural immune response against Human Papilloma Virus, or HPV. Based on the drug profiling Cassiopea has performed to date, the Company believes CB-06-02 has the potential to have a faster onset of action and a lower recurrence rate than currently available treatments.

CB-06-02 gel was previously tested in subjects with external genital warts in an open label study to assess the safety and efficacy of the improved formulation of the CB-06-02 gel. In the study (ended July 2013), the BAS024 formulation was tested in 11 female subjects with external genital warts who applied the formulation twice daily for up to 16 weeks. Efficacy and safety data were collected; data regarding the satisfaction of the subjects from the treatment, comfort of application, etc. was collected as well. The treatment was found safe and tolerable, showing relatively minimal skin irritation and no SAEs. Complete clearance of warts was achieved by 8 (73%) of the treated subjects while all 3 other subjects achieved partial clearance. No recurrence was observed during 3 months post treatment follow up. The CB-06-02 gel was highly graded for comfort and easy to apply by most of the participants.




Provider
Channel
Contact
Tensid EQS Ltd., Switzerland
www.tensid.ch


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CASSIOPEA SPA
08/20Cassiopea Announces FDA Submission of New Drug Application for Clascoterone C..
TE
07/18Cassiopea Announces Results for First Half of 2019
TE
05/08COSMO PHARMACEUTICALS : FDA Allowance of IND application for CB-03-10
AQ
04/16Cassiopea Announces Very Positive Phase II Twelve Months Results for Breezula..
TE
04/01Cosmo Full-Year Report 2018
AQ
03/26Cassiopea Announces Positive Results from Phase III Acne Open-Label Safety St..
TE
03/19Cassiopea announces results of ordinary and extraordinary shareholders meetin..
TE
02/08Cassiopea announces 2018 Results in line with expectations
TE
2018Cassiopea announces attainment of all primary and secondary endpoints and hig..
TE
2018Cassiopea enters into loan agreement with Cosmo Pharmaceuticals NV
TE
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -17,8 M
Net income 2019 -19,4 M
Debt 2019 18,1 M
Yield 2019 -
P/E ratio 2019 -18,4x
P/E ratio 2020 -9,85x
EV / Sales2019 infx
EV / Sales2020 7,34x
Capitalization 382 M
Chart CASSIOPEA SPA
Duration : Period :
Cassiopea SpA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CASSIOPEA SPA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 75,27  €
Last Close Price 38,21  €
Spread / Highest target 140%
Spread / Average Target 97,0%
Spread / Lowest Target 65,4%
EPS Revisions
Managers
NameTitle
Diana Harbort Chief Executive Officer & Executive Director
Jan Egbert de Vries Non-Executive Chairman
Marco Pasero Chief Operating Officer
Hans Christoph Tanner CFO, Head-Investor & Media Relations
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CASSIOPEA SPA13.39%424
GILEAD SCIENCES1.42%80 344
VERTEX PHARMACEUTICALS10.87%47 223
REGENERON PHARMACEUTICALS-20.74%32 392
GENMAB28.01%13 210
NEUROCRINE BIOSCIENCES, INC.35.88%8 886